|
시장보고서
상품코드
1671185
세계의 항응고제 역전약 시장 규모, 점유율, 동향, 업계 분석 : 제품별, 유통 채널별, 지역별 - 예측(2025-2034년)Anticoagulant Reversal Drugs Market Share, Size, Trends, Industry Analysis Report - By Product, Distribution Channel, and Region - Market Forecast, 2025-2034 |
||||||
Polaris Market Research의 최신 조사에 따르면 항응고제 역전약 시장 규모는 2034년까지 44억 8,647만 달러에 달할 전망입니다. 이 리포트에서는 현재 시장 역학의 상세 인사이트와 향후 시장 성장에 관한 분석을 제공하고 있습니다.
심방세동, 심장마비 등 심혈관 질환은 전 세계에서 보편화되어 있습니다. 이러한 질환을 가진 환자들은 혈전을 예방하기 위해 항응고제(혈액 희석제)를 복용해야 합니다. 그러나 항응고제는 경우에 따라 과다 출혈의 위험을 증가시킬 수 있으며, 잠재적인 출혈성 합병증을 관리하기 위해 항응고제 역전제의 필요성이 발생합니다. 심혈관 질환을 앓고 있는 환자 수가 증가함에 따라 이러한 역전제에 대한 수요가 증가하고 있습니다. 따라서 치료 중 환자의 안전을 보장하기 위해 치료 과정의 중요한 부분이 되고 있습니다. 심혈관 질환의 유병률 증가는 항응고제 역전제 시장 수요를 직접적으로 촉진하고 있습니다.
FDA와 같은 규제기관이 새롭고 효과적인 항응고제 역전제를 승인하는 것은 항응고제 역전제 시장의 성장을 가속하고 있으며, FDA의 승인은 의약품이 안전하고 효과적이라는 것을 보장하고 의료 프로바이더와 환자들 사이에 신뢰를 구축합니다. 새로운 역전 약물이 도입되고 승인되면 의사는 치료 옵션을 늘려 각 환자에게 가장 적합한 약물을 선택할 수 있게 됩니다. 이렇게 승인된 약품이 늘어나면 의료 시스템이 새로운 치료법을 채택하게 되고, 시장이 활성화됩니다. 이러한 약물의 지속적인 승인은 증가하는 의료 수요에 대응하고 항응고제 역전제 시장 개발을 촉진하는 데 도움이 됩니다.
항응고제 역전제 시장 보고서 하이라이트
제품별로 보면 이달시주맙 부문은 일반적인 혈액 희석제인 다비가트란의 작용을 역전시키는 높은 효능과 특이성으로 인해 2024년 항응고제 역전제 시장 점유율을 독점했습니다.
병원약국 시장은 출혈성 질환으로 인한 입원환자 증가로 인해 가장 큰 시장 점유율을 차지하고 있습니다.
2024년 북미가 전체 항응고제 역전제 시장 매출 점유율을 독점했으며, 이는 직접 환급 정책의 가용성과 이 지역의 첨단화된 헬스케어 부문 등의 요인에 기인합니다.
아시아태평양의 항응고제 역전제 시장은 헬스케어 투자 증가와 혈액 희석제 치료에 대한 인식이 높아짐에 따라 크게 성장하고 있습니다.
세계의 시장 기업으로는 Alps Pharmaceutical Ind. Co., Ltd., AMAG Pharmaceuticals, Inc., Bausch Health Companies Inc., Boehringer Ingelheim, CSL Behring, Dr. Reddy's Laboratories, Fresenius Kabi AG, Octapharma AG, Pfizer, Inc., Portola Pharmaceuticals, Covis Pharma., Hisamitsu Pharmaceutical Co., Inc. 등이 있습니다.
목차
제1장 서론
제2장 개요
제3장 분석 방법
제4장 세계의 항응고제 역전약 시장 인사이트
- 시장 스냅숏
- 항응고제 역전약 시장 역학
- 촉진요인과 기회
- 연구 활동의 확대
- 고령자 인구의 증가
- 억제요인과 과제
- 규제상 허들
- 촉진요인과 기회
- PESTLE 분석
- 항응고제 역전약 시장 동향
- 밸류체인 분석
- COVID-19의 영향 분석
제5장 세계의 항응고제 역전약 시장 : 제품별
- 주요 분석 결과
- 서론
- 프로트롬빈 복합체 농축물
- Phytonadione
- Andexanet Alfa
- Idarucizumab
- 프로타민
제6장 세계의 항응고제 역전약 시장 : 유통 채널별
- 주요 분석 결과
- 서론
- 병원 약국
- 소매 약국
- 온라인 약국
제7장 세계의 항응고제 역전약 시장 : 지역별
- 주요 분석 결과
- 서론
- 항응고제 역전약 시장 평가 : 지역별(2020-2034년)
- 북미
- 북미 : 제품별(2020-2034년)
- 북미 : 유통 채널별(2020-2034년)
- 미국
- 캐나다
- 유럽
- 유럽 : 제품별(2020-2034년)
- 유럽 : 유통 채널별(2020-2034년)
- 영국
- 프랑스
- 독일
- 이탈리아
- 스페인
- 네덜란드
- 러시아
- 기타 유럽
- 아시아태평양
- 아시아태평양 : 제품별(2020-2034년)
- 아시아태평양 : 유통 채널별(2020-2034년)
- 중국
- 인도
- 말레이시아
- 일본
- 인도네시아
- 한국
- 호주
- 기타 아시아태평양
- 중동 및 아프리카
- 중동 및 아프리카 : 제품별(2020-2034년)
- 중동 및 아프리카 : 유통 채널별(2020-2034년)
- 사우디아라비아
- 아랍에미리트
- 이스라엘
- 남아프리카공화국
- 기타 중동 및 아프리카
- 라틴아메리카
- 라틴아메리카 : 제품별(2020-2034년)
- 라틴아메리카 : 유통 채널별(2020-2034년)
- 멕시코
- 브라질
- 아르헨티나
- 기타 라틴아메리카
제8장 경쟁 구도
- 사업 확대·기업 인수 분석
- 사업 확대
- 기업 인수
- 제휴/협업/합의/공개
제9장 기업 개요
- Alps Pharmaceutical Ind. Co., Ltd.
- AMAG Pharmaceuticals, Inc.
- Bausch Health Companies Inc.
- Boehringer Ingelheim
- CSL Behring
- Dr. Reddy's Laboratories
- Fresenius Kabi AG
- Octapharma AG
- Pfizer, Inc.
- Portola Pharmaceuticals
- Covis Pharma
- Hisamitsu Pharmaceutical Co., Inc.
The anticoagulant reversal drugs market size is expected to reach USD 4,486.47 million by 2034, according to a new study by Polaris Market Research. The report "Anticoagulant Reversal Drugs Market Share, Size, Trends, Industry Analysis Report - By Product (Prothrombin Complex Concentrates, Phytonadione, Andexanet Alfa, Idarucizumab, Protamine, and Others), Distribution Channel, and Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Forecast, 2025-2034" gives a detailed insight into current market dynamics and provides analysis on future market growth.
Cardiovascular diseases, such as atrial fibrillation and heart attacks, are becoming common worldwide. Patients having these conditions require anticoagulants (blood thinners) to prevent blood clots. However, anticoagulants can increase the risk of excessive bleeding in some cases, creating a need for anticoagulant reversal drugs to manage potential bleeding complications. The growing number of individuals affected by cardiovascular conditions leads to an increased demand for these reversal drugs. This makes them an essential part of the treatment process, ensuring patient safety during therapy. The rise in the prevalence of cardiovascular diseases is directly driving the anticoagulant reversal drugs market demand.
The approval of new and effective anticoagulant reversal drugs by regulatory authorities such as the FDA is driving the anticoagulant reversal drug market growth. FDA approval ensures that a drug is safe and effective for public use, which builds trust among healthcare providers and patients. When new reversal drugs are introduced and approved, they provide more treatment options for doctors, allowing them to select the most appropriate medicine for each patient. This increased availability of approved drugs stimulates the market as healthcare systems adopt these newer treatments. The continuous approval of such drugs helps meet the growing healthcare demand, driving the anticoagulant reversal drugs market development.
Anticoagulant Reversal Drugs Market Report Highlights
By product, the idarucizumab segment dominated the anticoagulant reversal drugs market share in 2024 due to its high efficacy and specificity in reversing the effects of dabigatran, a common blood thinner.
The hospital pharmacy segment, based on distribution channel, accounts for the largest market share due to rising hospital admissions for distinct types of bleeding disorders.
In 2024, North America dominated the overall anticoagulant reversal drugs market revenue share due to factors such as the availability of direct refund policies and the region's advanced healthcare sector.
The Asia Pacific anticoagulant reversal drug market is experiencing significant growth due to increasing healthcare investments and rising awareness about blood thinning treatments.
A few global market players include Alps Pharmaceutical Ind. Co., Ltd.; AMAG Pharmaceuticals, Inc.; Bausch Health Companies Inc.; Boehringer Ingelheim; CSL Behring; Dr. Reddy's Laboratories; Fresenius Kabi AG; Octapharma AG; Pfizer, Inc.; Portola Pharmaceuticals; Covis Pharma.; and Hisamitsu Pharmaceutical Co., Inc.
Polaris Market Research has segmented the anticoagulant reversal drugs market report on the basis of product, distribution channel, and region:
By Product Outlook (Revenue - USD Million, 2020-2034)
- Prothrombin Complex Concentrates
- Phytonadione
- Andexanet Alfa
- Idarucizumab
- Protamine
By Distribution Channel Outlook (Revenue - USD Million, 2020-2034)
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
By Regional Outlook (Revenue - USD Million, 2020-2034)
- North America
- US
- Canada
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Russia
- Netherlands
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- South Korea
- Indonesia
- Malaysia
- Australia
- Vietnam
- Rest of Asia Pacific
- Latin America
- Argentina
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa
- UAE
- Saudi Arabia
- Israel
- South Africa
- Rest of Middle East & Africa
Table of Contents
1. Introduction
- 1.1. Report Description
- 1.1.1. Objectives of the Study
- 1.1.2. Market Scope
- 1.1.3. Assumptions
- 1.2. Stakeholders
2. Executive Summary
- 2.1. Market Highlights
3. Research Methodology
- 3.1. Overview
- 3.1.1. Data Mining
- 3.2. Data Sources
- 3.2.1. Primary Sources
- 3.2.2. Secondary Sources
4. Global Anticoagulant Reversal Drugs Market Insights
- 4.1. Anticoagulant Reversal Drugs Market - Market Snapshot
- 4.2. Anticoagulant Reversal Drugs Market Dynamics
- 4.2.1. Drivers and Opportunities
- 4.2.1.1. Increasing Research Activities
- 4.2.1.2. Rise in Geriatric Population
- 4.2.2. Restraints and Challenges
- 4.2.2.1. Regulatory Hurdle
- 4.2.1. Drivers and Opportunities
- 4.3. Porter's Five Forces Analysis
- 4.3.1. Bargaining Power of Suppliers (Moderate)
- 4.3.2. Threats of New Entrants: (Low)
- 4.3.3. Bargaining Power of Buyers (Moderate)
- 4.3.4. Threat of Substitute (Moderate)
- 4.3.5. Rivalry among existing firms (High)
- 4.4. PESTEL Analysis
- 4.5. Anticoagulant Reversal Drugs Market Distribution Channel Trends
- 4.6. Value Chain Analysis
- 4.7. COVID-19 Impact Analysis
5. Global Anticoagulant Reversal Drugs Market, by Product
- 5.1. Key Findings
- 5.2. Introduction
- 5.2.1. Global Anticoagulant Reversal Drugs Market, by Product, 2020-2034 (USD Million)
- 5.3. Prothrombin Complex Concentrates
- 5.3.1. Global Anticoagulant Reversal Drugs Market, by Prothrombin Complex Concentrates, by Region, 2020-2034 (USD Million)
- 5.4. Phytonadione
- 5.4.1. Global Anticoagulant Reversal Drugs Market, by Phytonadione, by Region, 2020-2034 (USD Million)
- 5.5. Andexanet Alfa
- 5.5.1. Global Anticoagulant Reversal Drugs Market, by Andexanet Alfa, by Region, 2020-2034 (USD Million)
- 5.6. Idarucizumab
- 5.6.1. Global Anticoagulant Reversal Drugs Market, by Idarucizumab, by Region, 2020-2034 (USD Million)
- 5.7. Protamine
- 5.7.1. Global Anticoagulant Reversal Drugs Market, by Protamine, by Region, 2020-2034 (USD Million)
6. Global Anticoagulant Reversal Drugs Market, by Distribution Channel
- 6.1. Key Findings
- 6.2. Introduction
- 6.2.1. Global Anticoagulant Reversal Drugs Market, by Distribution Channel, 2020-2034 (USD Million)
- 6.3. Hospital Pharmacy
- 6.3.1. Global Anticoagulant Reversal Drugs Market, by Hospital Pharmacy, by Region, 2020-2034 (USD Million)
- 6.4. Retail Pharmacy
- 6.4.1. Global Anticoagulant Reversal Drugs Market, by Retail Pharmacy by Region, 2020-2034 (USD Million)
- 6.5. Online Pharmacy
- 6.5.1. Global Anticoagulant Reversal Drugs Market, by Online Pharmacy by Region, 2020-2034 (USD Million)
7. Global Anticoagulant Reversal Drugs Market, by Geography
- 7.1. Key Findings
- 7.2. Introduction
- 7.2.1. Anticoagulant Reversal Drugs Market Assessment, By Geography, 2020-2034 (USD Million)
- 7.3. Anticoagulant Reversal Drugs Market - North America
- 7.3.1. North America: Anticoagulant Reversal Drugs Market, by Product, 2020-2034 (USD Million)
- 7.3.2. North America: Anticoagulant Reversal Drugs Market, by Distribution Channel, 2020-2034 (USD Million)
- 7.3.3. Anticoagulant Reversal Drugs Market - U.S.
- 7.3.3.1. U.S.: Anticoagulant Reversal Drugs Market, by Product, 2020-2034 (USD Million)
- 7.3.3.2. U.S.: Anticoagulant Reversal Drugs Market, by Distribution Channel, 2020-2034 (USD Million)
- 7.3.4. Anticoagulant Reversal Drugs Market - Canada
- 7.3.4.1. Canada: Anticoagulant Reversal Drugs Market, by Product, 2020-2034 (USD Million)
- 7.3.4.2. Canada: Anticoagulant Reversal Drugs Market, by Distribution Channel, 2020-2034 (USD Million)
- 7.4. Anticoagulant Reversal Drugs Market - Europe
- 7.4.1. Europe: Anticoagulant Reversal Drugs Market, by Product, 2020-2034 (USD Million)
- 7.4.2. Europe: Anticoagulant Reversal Drugs Market, by Distribution Channel, 2020-2034 (USD Million)
- 7.4.3. Anticoagulant Reversal Drugs Market - UK
- 7.4.3.1. UK: Anticoagulant Reversal Drugs Market, by Product, 2020-2034 (USD Million)
- 7.4.3.2. UK: Anticoagulant Reversal Drugs Market, by Distribution Channel, 2020-2034 (USD Million)
- 7.4.4. Anticoagulant Reversal Drugs Market - France
- 7.4.4.1. France: Anticoagulant Reversal Drugs Market, by Product, 2020-2034 (USD Million)
- 7.4.4.2. France: Anticoagulant Reversal Drugs Market, by Distribution Channel, 2020-2034 (USD Million)
- 7.4.5. Anticoagulant Reversal Drugs Market - Germany
- 7.4.5.1. Germany: Anticoagulant Reversal Drugs Market, by Product, 2020-2034 (USD Million)
- 7.4.5.2. Germany: Anticoagulant Reversal Drugs Market, by Distribution Channel, 2020-2034 (USD Million)
- 7.4.6. Anticoagulant Reversal Drugs Market - Italy
- 7.4.6.1. Italy: Anticoagulant Reversal Drugs Market, by Product, 2020-2034 (USD Million)
- 7.4.6.2. Italy: Anticoagulant Reversal Drugs Market, by Distribution Channel, 2020-2034 (USD Million)
- 7.4.7. Anticoagulant Reversal Drugs Market - Spain
- 7.4.7.1. Spain: Anticoagulant Reversal Drugs Market, by Product, 2020-2034 (USD Million)
- 7.4.7.2. Spain: Anticoagulant Reversal Drugs Market, by Distribution Channel, 2020-2034 (USD Million)
- 7.4.8. Anticoagulant Reversal Drugs Market - Netherlands
- 7.4.8.1. Netherlands: Anticoagulant Reversal Drugs Market, by Product, 2020-2034 (USD Million)
- 7.4.8.2. Netherlands: Anticoagulant Reversal Drugs Market, by Distribution Channel, 2020-2034 (USD Million)
- 7.4.9. Anticoagulant Reversal Drugs Market - Russia
- 7.4.9.1. Russia: Anticoagulant Reversal Drugs Market, by Product, 2020-2034 (USD Million)
- 7.4.9.2. Russia: Anticoagulant Reversal Drugs Market, by Distribution Channel, 2020-2034 (USD Million)
- 7.4.10. Anticoagulant Reversal Drugs Market - Rest of Europe
- 7.4.10.1. Rest of Europe: Anticoagulant Reversal Drugs Market, by Product, 2020-2034 (USD Million)
- 7.4.10.2. Rest of Europe: Anticoagulant Reversal Drugs Market, by Distribution Channel, 2020-2034 (USD Million)
- 7.5. Anticoagulant Reversal Drugs Market - Asia Pacific
- 7.5.1. Asia Pacific: Anticoagulant Reversal Drugs Market, by Product, 2020-2034 (USD Million)
- 7.5.2. Asia Pacific: Anticoagulant Reversal Drugs Market, by Distribution Channel, 2020-2034 (USD Million)
- 7.5.3. Anticoagulant Reversal Drugs Market - China
- 7.5.3.1. China: Anticoagulant Reversal Drugs Market, by Product, 2020-2034 (USD Million)
- 7.5.3.2. China: Anticoagulant Reversal Drugs Market, by Distribution Channel, 2020-2034 (USD Million)
- 7.5.4. Anticoagulant Reversal Drugs Market - India
- 7.5.4.1. India: Anticoagulant Reversal Drugs Market, by Product, 2020-2034 (USD Million)
- 7.5.4.2. India: Anticoagulant Reversal Drugs Market, by Distribution Channel, 2020-2034 (USD Million)
- 7.5.5. Anticoagulant Reversal Drugs Market - Malaysia
- 7.5.5.1. Malaysia: Anticoagulant Reversal Drugs Market, by Product, 2020-2034 (USD Million)
- 7.5.5.2. Malaysia: Anticoagulant Reversal Drugs Market, by Distribution Channel, 2020-2034 (USD Million)
- 7.5.6. Anticoagulant Reversal Drugs Market - Japan
- 7.5.6.1. Japan: Anticoagulant Reversal Drugs Market, by Product, 2020-2034 (USD Million)
- 7.5.6.2. Japan: Anticoagulant Reversal Drugs Market, by Distribution Channel, 2020-2034 (USD Million)
- 7.5.7. Anticoagulant Reversal Drugs Market - Indonesia
- 7.5.7.1. Indonesia: Anticoagulant Reversal Drugs Market, by Product, 2020-2034 (USD Million)
- 7.5.7.2. Indonesia: Anticoagulant Reversal Drugs Market, by Distribution Channel, 2020-2034 (USD Million)
- 7.5.8. Anticoagulant Reversal Drugs Market - South Korea
- 7.5.8.1. South Korea: Anticoagulant Reversal Drugs Market, by Product, 2020-2034 (USD Million)
- 7.5.8.2. South Korea: Anticoagulant Reversal Drugs Market, by Distribution Channel, 2020-2034 (USD Million)
- 7.5.9. Anticoagulant Reversal Drugs Market - Australia
- 7.5.9.1. Australia: Anticoagulant Reversal Drugs Market, by Product, 2020-2034 (USD Million)
- 7.5.9.2. Australia: Anticoagulant Reversal Drugs Market, by Distribution Channel, 2020-2034 (USD Million)
- 7.5.10. Anticoagulant Reversal Drugs Market - Rest of Asia Pacific
- 7.5.10.1. Rest of Asia Pacific: Anticoagulant Reversal Drugs Market, by Product, 2020-2034 (USD Million)
- 7.5.10.2. Rest of Asia Pacific: Anticoagulant Reversal Drugs Market, by Distribution Channel, 2020-2034 (USD Million)
- 7.6. Anticoagulant Reversal Drugs Market - Middle East & Africa
- 7.6.1. Middle East & Africa: Anticoagulant Reversal Drugs Market, by Product, 2020-2034 (USD Million)
- 7.6.2. Middle East & Africa: Anticoagulant Reversal Drugs Market, by Distribution Channel, 2020-2034 (USD Million)
- 7.6.3. Anticoagulant Reversal Drugs Market - Saudi Arabia
- 7.6.3.1. Saudi Arabia: Anticoagulant Reversal Drugs Market, by Product, 2020-2034 (USD Million)
- 7.6.3.2. Saudi Arabia: Anticoagulant Reversal Drugs Market, by Distribution Channel, 2020-2034 (USD Million)
- 7.6.4. Anticoagulant Reversal Drugs Market - UAE
- 7.6.4.1. UAE: Anticoagulant Reversal Drugs Market, by Product, 2020-2034 (USD Million)
- 7.6.4.2. UAE: Anticoagulant Reversal Drugs Market, by Distribution Channel, 2020-2034 (USD Million)
- 7.6.5. Anticoagulant Reversal Drugs Market - Israel
- 7.6.5.1. Israel: Anticoagulant Reversal Drugs Market, by Product, 2020-2034 (USD Million)
- 7.6.5.2. Israel: Anticoagulant Reversal Drugs Market, by Distribution Channel, 2020-2034 (USD Million)
- 7.6.6. Anticoagulant Reversal Drugs Market - South Africa
- 7.6.6.1. South Africa: Anticoagulant Reversal Drugs Market, by Product, 2020-2034 (USD Million)
- 7.6.6.2. South Africa: Anticoagulant Reversal Drugs Market, by Distribution Channel, 2020-2034 (USD Million)
- 7.6.7. Anticoagulant Reversal Drugs Market - Rest of Middle East & Africa
- 7.6.7.1. Rest of Middle East & Africa: Anticoagulant Reversal Drugs Market, by Product, 2020-2034 (USD Million)
- 7.6.7.2. Rest of Middle East & Africa: Anticoagulant Reversal Drugs Market, by Distribution Channel, 2020-2034 (USD Million)
- 7.7. Anticoagulant Reversal Drugs Market - Latin America
- 7.7.1. Latin America: Anticoagulant Reversal Drugs Market, by Product, 2020-2034 (USD Million)
- 7.7.2. Latin America: Anticoagulant Reversal Drugs Market, by Distribution Channel, 2020-2034 (USD Million)
- 7.7.3. Anticoagulant Reversal Drugs Market - Mexico
- 7.7.3.1. Mexico: Anticoagulant Reversal Drugs Market, by Product, 2020-2034 (USD Million)
- 7.7.3.2. Mexico: Anticoagulant Reversal Drugs Market, by Distribution Channel, 2020-2034 (USD Million)
- 7.7.4. Anticoagulant Reversal Drugs Market - Brazil
- 7.7.4.1. Brazil: Anticoagulant Reversal Drugs Market, by Product, 2020-2034 (USD Million)
- 7.7.4.2. Brazil: Anticoagulant Reversal Drugs Market, by Distribution Channel, 2020-2034 (USD Million)
- 7.7.5. Anticoagulant Reversal Drugs Market - Argentina
- 7.7.5.1. Argentina: Anticoagulant Reversal Drugs Market, by Product, 2020-2034 (USD Million)
- 7.7.5.2. Argentina: Anticoagulant Reversal Drugs Market, by Distribution Channel, 2020-2034 (USD Million)
- 7.7.6. Anticoagulant Reversal Drugs Market - Rest of Latin America
- 7.7.6.1. Rest of Latin America: Anticoagulant Reversal Drugs Market, by Product, 2020-2034 (USD Million)
- 7.7.6.2. Rest of Latin America: Anticoagulant Reversal Drugs Market, by Distribution Channel, 2020-2034 (USD Million)
8. Competitive Landscape
- 8.1. Expansion and Acquisition Analysis
- 8.1.1. Expansion
- 8.1.2. Acquisitions
- 8.2. Partnerships/Collaborations/Agreements/Exhibitions
9. Company Profiles
- 9.1. Alps Pharmaceutical Ind. Co., Ltd.
- 9.1.1. Company Overview
- 9.1.2. Financial Performance
- 9.1.3. Product Benchmarking
- 9.1.4. Recent Development
- 9.2. AMAG Pharmaceuticals, Inc.
- 9.2.1. Company Overview
- 9.2.2. Financial Performance
- 9.2.3. Product Benchmarking
- 9.2.4. Recent Development
- 9.3. Bausch Health Companies Inc.
- 9.3.1. Company Overview
- 9.3.2. Financial Performance
- 9.3.3. Product Benchmarking
- 9.3.4. Recent Development
- 9.4. Boehringer Ingelheim
- 9.4.1. Company Overview
- 9.4.2. Financial Performance
- 9.4.3. Product Benchmarking
- 9.4.4. Recent Development
- 9.5. CSL Behring
- 9.5.1. Company Overview
- 9.5.2. Financial Performance
- 9.5.3. Product Benchmarking
- 9.5.4. Recent Development
- 9.6. Dr. Reddy's Laboratories
- 9.6.1. Company Overview
- 9.6.2. Financial Performance
- 9.6.3. Product Benchmarking
- 9.6.4. Recent Development
- 9.7. Fresenius Kabi AG
- 9.7.1. Company Overview
- 9.7.2. Financial Performance
- 9.7.3. Product Benchmarking
- 9.7.4. Recent Development
- 9.8. Octapharma AG
- 9.8.1. Company Overview
- 9.8.2. Financial Performance
- 9.8.3. Product Benchmarking
- 9.8.4. Recent Development
- 9.9. Pfizer, Inc.
- 9.9.1. Company Overview
- 9.9.2. Financial Performance
- 9.9.3. Product Benchmarking
- 9.9.4. Recent Development
- 9.10. Portola Pharmaceuticals
- 9.10.1. Company Overview
- 9.10.2. Financial Performance
- 9.10.3. Product Benchmarking
- 9.10.4. Recent Development
- 9.11. Covis Pharma
- 9.11.1. Company Overview
- 9.11.2. Financial Performance
- 9.11.3. Product Benchmarking
- 9.11.4. Recent Development
- 9.12. Hisamitsu Pharmaceutical Co., Inc.
- 9.12.1. Company Overview
- 9.12.2. Financial Performance
- 9.12.3. Product Benchmarking
- 9.12.4. Recent Development
